title: Small molecule integrin antagonists in cancer therapy.
abstract: Integrins are a large family of dimeric receptors composed by alpha and beta subunits that, once bound to extra-cellular matrix (ECM) proteins, regulate a variety of cellular processes such as cell motility, migration, and proliferation. The integrins transduce signals from inside-out and outside-in the cell, thus representing the cellular link to the external environment. For these properties, integrin activation has been involved in pathological processes like tumor growth and metastasis formation. Recent advances in the elucidation of the crystallographic structures of the alphavbeta3 and alphaIIbeta3 integrins are promoting studies focused to the search of small molecule antagonists that can block the integrin binding to ECM and inhibit the biological effects exerted by these receptors. In this review we will focus on small molecule antagonists of alphavbeta3 and alphavbeta5 integrin as tools for cancer therapy while other integrins will only be briefly mentioned. Cilengitide (cyclic peptidic alphavbeta3 and alphavbeta5 antagonist) is currently in clinical trials for anti cancer therapy. Combination of integrin alphavbeta3 antagonists and other traditional therapeutic approaches may represent a future strategy to inhibit tumor growth and metastasis spreading.
authors.affiliation: Dipartimento di Farmacologia Sperimentale ed Applicata, Università di Pavia, Italy. mayra.paolillo@unipv.it
authors.forename: Mayra
authors.initials: M
authors.lastname: Paolillo
authors.forename: Marika A
authors.initials: MA
authors.lastname: Russo
authors.forename: Massimo
authors.initials: M
authors.lastname: Serra
authors.forename: Lino
authors.initials: L
authors.lastname: Colombo
authors.forename: Sergio
authors.initials: S
authors.lastname: Schinelli
mesh_terms: D023102:Anoikis; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000494:pharmacology; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D016023:Integrins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy*; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D015398:Signal Transduction; D012910:Snake Venoms / Q000737:chemistry / Q000494:pharmacology; D013449:Sulfonamides / Q000737:chemistry / Q000494:pharmacology
chemical_list: D007211:Indoles; D039302:Integrin alphaVbeta3; D016023:Integrins; D010455:Peptides; D019030:Receptors, Vitronectin; D012910:Snake Venoms; D013449:Sulfonamides; C064660:integrin alphaVbeta5; C468872:N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide; C422910:Cilengitide